Literature DB >> 33632914

Epidemiological characteristics of cervical cancer in a tertiary care hospital, western Saudi Arabia: A retrospective record-based analysis from 2002-2018.

Fayssal M Farahat1, Norah T Faqih1, Razan S Alharbi1, Raheed I Mudarris1, Sahl A Alshaikh1, Hatim M Al-Jifree1.   

Abstract

OBJECTIVES: To investigate the epidemiological characteristics of cervical cancer cases reported at a tertiary care teaching hospital in western Saudi Arabia.
METHODS: A retrospective chart review was conducted on medical records of patients diagnosed with cervical cancer at King Abdulaziz Medical City, Jeddah, Saudi Arabia. Data were collected on demographic characteristics, histological types and stage, treatment modalities, and disease outcomes.
RESULTS: Cervical cancer was diagnosed among 89 patients from 2002 to 2018. History of pap smear was reported among 31 cases (34.8%). Squamous cell carcinoma was the most common reported histopathological subtype. Almost one third (29.2%) of the patients were at stage III or IV at the time of diagnosis. The most frequent treatment regimen was combined radio/chemotherapy. Kaplan-Meier analysis showed an overall survival rate of 81.5%.
CONCLUSION: The lack of an effective screening program for cervical cancer increases the likelihood of a late diagnosis and higher rates of complications and mortality. Public health programs should focus on cancer screening, screening, and reporting HPV infections, and supporting HPV vaccination activities. Copyright: © Saudi Medical Journal.

Entities:  

Keywords:  cervical cancer; elimination; human papillomavirus; incidence

Mesh:

Year:  2021        PMID: 33632914     DOI: 10.15537/smj.2021.42.3.20200603

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  1 in total

1.  Awareness and Practices Related to Cervical Cancer among Females in Saudi Arabia.

Authors:  Heba M Zahid; Alma B Qarah; Amal M Alharbi; Arwa E Alomar; Shaimaa A Almubarak
Journal:  Int J Environ Res Public Health       Date:  2022-01-27       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.